Schizophrenia Research
Volume 118, Issue 1 , Pages 211-217 , May 2010

Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia

  • Xiaoduo Fan

      Affiliations

    • Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    • Harvard Medical School, Boston, MA, United States
    • Corresponding Author InformationCorresponding author. Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, United States. Tel.: +1 617 912 7800; fax: +1 617 723 3919.
    • ,
  • Emily Y. Liu

      Affiliations

    • Partners Community Healthcare, Inc., Haverhill, MA, United States
    • ,
  • Oliver Freudenreich

      Affiliations

    • Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    • Harvard Medical School, Boston, MA, United States
    • ,
  • Ju Hyung Park

      Affiliations

    • Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    • ,
  • Dengtang Liu

      Affiliations

    • Shanghai Mental Health Center, Shanghai, China
    • ,
  • Jijun Wang

      Affiliations

    • Shanghai Mental Health Center, Shanghai, China
    • ,
  • Zhenghui Yi

      Affiliations

    • Shanghai Mental Health Center, Shanghai, China
    • ,
  • Donald Goff

      Affiliations

    • Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    • Harvard Medical School, Boston, MA, United States
    • ,
  • David C. Henderson

      Affiliations

    • Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    • Harvard Medical School, Boston, MA, United States

Received 8 October 2009 ,Revised 2 February 2010 ,Accepted 3 February 2010.

References 

  1. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90(1–3):179–185
  2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–1696
  3. Bachneff SA. Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Schizophr Bull. 1996;22(1):163–182
  4. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93(1–3):261–265
  5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428
  6. el-Mallakh RS, Suddath RL , Wyatt RJ. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17(3):383–391
  7. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2006;149(1–3):267–271
  8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359
  9. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–3167
  10. Gillum RF, Ingram DD, Makuc DM. White blood cell count and stroke incidence and death. The NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994;139(9):894–902
  11. Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke. 2004;35(5):1147–1152
  12. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–438
  13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752
  14. Hansen K, Sickelmann F, Pietrowsky R, Fehm HL, Born J. Systemic immune changes following meal intake in humans. Am J Physiol. 1997;273(2 Pt 2):R548–R553
  15. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet. 2005;6:7
  16. Hardy TA, Marquez E, Kryzhanovskaya L, Taylor CC, Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol. 2006;26(4):405–408
  17. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62(1):19–28
  18. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867
  19. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796
  20. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54(8):2404–2414
  21. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry. 1993;50(8):624–635
  22. Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry. 2001;158(11):1797–1808
  23. Lao XQ, Neil Thomas G, Jiang C, Zhang W, Adab P, Lam TH, et al. White blood cell count and the metabolic syndrome in older Chinese: the Guangzhou Biobank Cohort Study. Atherosclerosis. 2008;201(2):418–424
  24. Li TL, Wu CL, Gleeson M, Williams C. The effects of pre-exercise high carbohydrate meals with different glycemic indices on blood leukocyte redistribution, IL-6, and hormonal responses during a subsequent prolonged exercise. Int J Sport Nutr Exerc Metab. 2004;14(6):647–656
  25. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry. 1993;150(9):1408–1410
  26. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res. 1998;32(1):9–15
  27. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169(2):203–214
  28. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med. 2005;165(5):500–508
  29. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995;152(9):1291–1297
  30. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32
  31. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89(6):2728–2735
  32. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159(6):1029–1034
  33. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr Res. 1997;26(2–3):227–233
  34. Ohshita K, Yamane K, Hanafusa M, Mori H, Mito K, Okubo M, et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diabetes Care. 2004;27(2):491–496
  35. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res. 1997;25(2):123–129
  36. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126
  37. Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS, et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2007;49(18):1841–1850
  38. Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J Autoimmun. 1996;9(5):661–666
  39. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116(7):1813–1822
  40. Shim WS, Kim HJ, Kang ES, Ahn CW, Lim SK, Lee HC, et al. The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;73(3):284–291
  41. Shinba T, Nagano M, Kariya N, Ogawa K, Shinozaki T, Shimosato S, et al. Near-infrared spectroscopy analysis of frontal lobe dysfunction in schizophrenia. Biol Psychiatry. 2004;55(2):154–164
  42. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006;22(1):4–10
  43. Thiemann S, Csernansky JG, Berger PA. Rating scales in research: the case of negative symptoms. Psychiatry Res. 1987;20(1):47–55
  44. Tian JY, Yang Y, Cheng Q, Huang HE, Li R, Jiang GX, et al. Association of WBC count and glucose metabolism among Chinese population aged 40years and over. Diabetes Res Clin Pract. 2008;82(1):132–138
  45. Vaiva G, Cottencin O, Llorca PM, Devos P, Dupont S, Mazas O, et al. Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):481–485
  46. Vieweg BW, Hedlund JL. Psychological screening inventory: a comprehensive review. J Clin Psychol. 1984;40(6):1382–1393
  47. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(2):455–461
  48. Weiss ST, Segal MR, Sparrow D, Wager C. Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. Am J Epidemiol. 1995;142(5):493–498
  49. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–1119
  50. White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997;40(2):S2–17
  51. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004;65(7):940–947

PII: S0920-9964(10)01114-X

doi: 10.1016/j.schres.2010.02.1028

Schizophrenia Research
Volume 118, Issue 1 , Pages 211-217 , May 2010

Article Tools

* Image Usage & Resolution